Pioglitazone and Quetiapine XR Pharmacogenetic Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pioglitazone for the Treatment of Bipolar Depression

NCT01717040

Bipolar Disorder Insulin Resistance

TERMINATED PHASE4

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

NCT00835120

Metabolic Syndrome Bipolar Depression Insulin Resistance

COMPLETED PHASE4

Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression

NCT04923204

Bipolar Disorder

COMPLETED

Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)

NCT01272531

Bipolar Affective Disorder

COMPLETED

Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression

NCT03567681

Bipolar Depression Treatment Effectiveness Measure-based Guidance

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Seroquel

Participants who received Seroquel

No interventions assigned to this group

Pioglitazone

Participants who received pioglitazone

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have participated in IRB protocols 10-06-19, 12-07-29, 07-07-20, and 07-08-24
* Patient must give consent to participate, sign and date the IRB approved written informed consent form prior to the initiation of any procedures for this study
* Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder
* Patient must be at least 18 years old
* Patient must be willing to give a blood sample